Therapeutic antibodies: What have we learnt from targeting CD20 and where are we going?
Therapeutic antibodies: What have we learnt from targeting CD20 and where are we going?
Marshall, Michael J.E.
ae47eb68-f597-4c49-aced-5e09c4fd1e0c
Stopforth, Richard
2d3e18ff-5563-4247-9150-f0f337fb585f
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Marshall, Michael J.E.
ae47eb68-f597-4c49-aced-5e09c4fd1e0c
Stopforth, Richard
2d3e18ff-5563-4247-9150-f0f337fb585f
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Marshall, Michael J.E., Stopforth, Richard and Cragg, Mark S.
(2017)
Therapeutic antibodies: What have we learnt from targeting CD20 and where are we going?
Frontiers in Immunology.
(doi:10.3389/fimmu.2017.01245).
Other
289045_Cragg_Original_Manuscript
- Accepted Manuscript
Text
fimmu-08-01245
- Version of Record
More information
Accepted/In Press date: 19 September 2017
e-pub ahead of print date: 4 October 2017
Identifiers
Local EPrints ID: 414771
URI: http://eprints.soton.ac.uk/id/eprint/414771
ISSN: 1664-3224
PURE UUID: ad886aed-bb28-46b8-b85e-142c474fef0e
Catalogue record
Date deposited: 10 Oct 2017 16:31
Last modified: 16 Mar 2024 02:58
Export record
Altmetrics
Contributors
Author:
Michael J.E. Marshall
Author:
Richard Stopforth
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics